Shevan Silva

442 total citations
18 papers, 354 citations indexed

About

Shevan Silva is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Cell Biology. According to data from OpenAlex, Shevan Silva has authored 18 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Cell Biology. Recurrent topics in Shevan Silva's work include Cancer, Hypoxia, and Metabolism (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Aldose Reductase and Taurine (7 papers). Shevan Silva is often cited by papers focused on Cancer, Hypoxia, and Metabolism (12 papers), Lung Cancer Treatments and Mutations (9 papers) and Aldose Reductase and Taurine (7 papers). Shevan Silva collaborates with scholars based in New Zealand, United States and United Kingdom. Shevan Silva's co-authors include Jeff B. Smaill, Adam V. Patterson, Jack U. Flanagan, C.J. Squire, James M. Dickson, Y. Yosaatmadja, Mark J. McKeage, Adriana Estrada‐Bernal, Robert C. Doebele and Laurent Rigoreau and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Shevan Silva

18 papers receiving 348 citations

Peers

Countries citing papers authored by Shevan Silva

Since Specialization

Citations

This map shows the geographic impact of Shevan Silva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shevan Silva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shevan Silva more than expected).

Fields of papers citing papers by Shevan Silva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shevan Silva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shevan Silva. The network helps show where Shevan Silva may publish in the future.

Co-authorship network of co-authors of Shevan Silva

This figure shows the co-authorship network connecting the top 25 collaborators of Shevan Silva. A scholar is included among the top collaborators of Shevan Silva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shevan Silva. Shevan Silva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506 2023 ·ACS Medicinal Chemistry Letters ·Amir Ashoorzadeh, Alexandra M. Mowday, Maria R. Abbattista, Christopher P. Guise, (unknown), Shevan Silva, Adam V. Patterson, Jeff B. Smaill	3
2	Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications 2022 ·Pharmaceuticals ·Amir Ashoorzadeh, Alexandra M. Mowday, Christopher P. Guise, Shevan Silva, (unknown), Maria R. Abbattista, Janine N. Copp, Elsie M. Williams, David F. Ackerley, Adam V. Patterson, Jeff B. Smaill	3
3	Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3 2021 ·Pharmaceuticals ·Maria R. Abbattista, Amir Ashoorzadeh, Christopher P. Guise, Alexandra M. Mowday, (unknown), Shevan Silva, Kevin O. Hicks, (unknown), (unknown), (unknown), Gareth A. Prosser, Neil Lambie, Gabi U. Dachs, David F. Ackerley, Jeff B. Smaill, Adam V. Patterson	7
4	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes 2020 ·Clinical Cancer Research ·Adriana Estrada‐Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, (unknown), Jeff B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele	71
5	Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers 2019 ·Cancer Research ·Hui Yu, Shevan Silva, Adriana Estrada‐Bernal, Chris Rivard, Fred R. Hirsch, (unknown), Jeff B. Smaill, Robert C. Doebele, Adam V. Patterson, (unknown), Vijaya G. Tirunagaru	3
6	Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers 2019 ·Hui Yu, Shevan Silva, Adriana Estrada‐Bernal, Chris Rivard, Fred R. Hirsch, (unknown), Jeff B. Smaill, Robert C. Doebele, Adam V. Patterson, (unknown), Vijaya G. Tirunagaru	1
7	Abstract A157: Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions 2018 ·Molecular Cancer Therapeutics ·Adriana Estrada‐Bernal, Andrea E. Doak, Anh T. Le, (unknown), Nan Chen, Shevan Silva, Jeff B. Smaill, Adam V. Patterson, Robert C. Doebele	16
8	Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy 2016 ·Biochemical Pharmacology ·Alexandra M. Mowday, Amir Ashoorzadeh, Elsie M. Williams, Janine N. Copp, Shevan Silva, (unknown), Maria R. Abbattista, Robert F. Anderson, Jack U. Flanagan, Christopher P. Guise, David F. Ackerley, Jeff B. Smaill, Adam V. Patterson	17
9	Development of biomarkers to guide the clinical development of tarloxotinib bromide, a hypoxia-activated irreversible EGFR/HER2 inhibitor. 2016 ·Journal of Clinical Oncology ·Adam V. Patterson, Randall J. Kimple, (unknown), Adam D. Swick, Christopher P. Guise, Maria R. Abbattista, (unknown), (unknown), Shevan Silva, Jessica D. Sun, Charles P. Hart, Tillman Pearce, Jeff B. Smaill	2
10	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed 2015 ·Journal of Structural Biology ·Y. Yosaatmadja, Shevan Silva, James M. Dickson, Adam V. Patterson, Jeff B. Smaill, Jack U. Flanagan, Mark J. McKeage, C.J. Squire	108
11	TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC. 2015 ·Journal of Clinical Oncology ·Adam V. Patterson, Shevan Silva, Christopher P. Guise, (unknown), Maria R. Abbattista, (unknown), Jessica D. Sun, Charles P. Hart, Tillman Pearce, Jeff B. Smaill	14
12	Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS) 2015 ·Molecular Cancer Therapeutics ·(unknown), Shevan Silva, Maria R. Abbattista, Christopher P. Guise, (unknown), Amir Ashoorzadeh, Charles P. Hart, Tillman Pearce, Jeff B. Smaill, Adam V. Patterson	4
13	Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy 2015 ·Molecular Cancer Therapeutics ·Shevan Silva, (unknown), Christopher P. Guise, Maria R. Abbattista, (unknown), Angus C. Grey, Robert G. Anderson, Amir Ashoorzadeh, Charles P. Hart, Tillman Pearce, Adam V. Patterson, Jeff B. Smaill	6
14	Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial 2015 ·Cancer Research ·Adam V. Patterson, Shevan Silva, Christopher P. Guise, Maria R. Abbattista, (unknown), (unknown), Charles P. Hart, Jessica D. Sun, Angus C. Grey, Amir Ashoorzadeh, Robert F. Anderson, Jeff B. Smaill	6
15	Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3) 2014 ·Bioorganic & Medicinal Chemistry ·Jack U. Flanagan, Graham J. Atwell, Daniel Heinrich, Darby G. Brooke, Shevan Silva, Laurent Rigoreau, Elisabeth Trivier, A.P. Turnbull, Tony Raynham, Stephen M. F. Jamieson, William A. Denny	32
16	Synthesis and structure–activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3 2013 ·European Journal of Medicinal Chemistry ·Daniel Heinrich, Jack U. Flanagan, Stephen M. F. Jamieson, Shevan Silva, Laurent Rigoreau, Elisabeth Trivier, Tony Raynham, A.P. Turnbull, William A. Denny	30
17	Abstract B278: PR610: A novel hypoxia-selective tyrosine kinase inhibitor in phase I clinical trial. 2013 ·Molecular Cancer Therapeutics ·Adam V. Patterson, Jagdish K. Jaiswal, (unknown), Maria R. Abbattista, Christopher P. Guise, Shevan Silva, Ho Lee, Guo‐Liang Lu, Robert F. Anderson, Teresa J. Melink, John Gutheil, Jeff B. Smaill	1
18	3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-β-Hydroxysteroid Dehydrogenase AKR1C3 2012 ·Journal of Medicinal Chemistry ·Stephen M. F. Jamieson, Darby G. Brooke, Daniel Heinrich, Graham J. Atwell, Shevan Silva, Emma Hamilton, A.P. Turnbull, Laurent Rigoreau, Elisabeth Trivier, Christelle Soudy, (unknown), Paul Owen, (unknown), Tony Raynham, Jack U. Flanagan, William A. Denny	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact